Clinical and Molecular Heterogeneity of Osteogenesis Imperfecta (Colloquium Series on Genomic and Molecular Medicine)

個数:
  • ポイントキャンペーン

Clinical and Molecular Heterogeneity of Osteogenesis Imperfecta (Colloquium Series on Genomic and Molecular Medicine)

  • ウェブストア価格 ¥6,166(本体¥5,606)
  • Morgan & Claypool Publishers(2017/01発売)
  • 外貨定価 US$ 30.00
  • 【ウェブストア限定】サマー!ポイント5倍キャンペーン 対象商品(~7/21)※店舗受取は対象外
  • ポイント 280pt
  • オンデマンド(OD/POD)版です。キャンセルは承れません。
  • 【入荷遅延について】
    世界情勢の影響により、海外からお取り寄せとなる洋書・洋古書の入荷が、表示している標準的な納期よりも遅延する場合がございます。
    おそれいりますが、あらかじめご了承くださいますようお願い申し上げます。
  • ◆画像の表紙や帯等は実物とは異なる場合があります。
  • ◆ウェブストアでの洋書販売価格は、弊社店舗等での販売価格とは異なります。
    また、洋書販売価格は、ご注文確定時点での日本円価格となります。
    ご注文確定後に、同じ洋書の販売価格が変動しても、それは反映されません。
  • 製本 Paperback:紙装版/ペーパーバック版/ページ数 63 p.
  • 言語 ENG
  • 商品コード 9781615047444
  • DDC分類 576.5

Full Description

Osteogenesis imperfecta (OI) is a disease encompassing a group of disorders mainly characterized by bone fragility and is the commonest form of heritable bone fragility. In this book, the clinical presentations with particular emphasis on rare phenotypes associated with OI are discussed together with molecular advances in diagnosis and treatment of OI. There is a broad spectrum of clinical severity in OI, ranging from multiple fractures in utero and perinatal death, to near-normal adult stature and low fracture incidence. Facial dysmorphism has been noted, but is not well described, nor is it an invariable feature. Sillence et al., in 1979, provided the clinical classification, which has been further expanded. Genetic defects in type 1 collagen can be identified in 85% of patients with a clinical diagnosis of OI, that is, mutations in COL1A1/COL1A2, which follows an autosomal dominant pattern of inheritance. Several genes have now been implicated in autosomal recessive forms of OI and X-linked osteoporosis. Given the possible antenatal presentation and prognosis associated with OI, it is important to make this diagnosis early and be able to distinguish this from other lethal skeletal dysplasias. It is also important to distinguish nonaccidental injury from a pathological cause of fractures, such as OI, and diagnose this promptly in these situations. However, this is not always possible due to variability in presentation and inability to pinpoint the precise genetic etiology despite extensive genetic testing. OI is one such rare genetic condition where treatment is available in the form of bisphosphonates, which has a huge impact on quality of life. Despite advances in medical therapy, multidisciplinary management including physiotherapy remains the mainstay of treatment and improved outcomes in OI.

Contents

Introduction
The Normal Bone
Osteogenesis Imperfecta
Molecular Heterogeneity of OI
Differential Diagnoses
Genetic Diagnosis and Management of OI
Therapeutic Approaches for OI
Comorbidities
Prognosis
Latest Developments
Conclusions
References
Glossary
Author Biography

最近チェックした商品